Carlos Cordon-Cardo

Carlos Cordon-Cardo's AcademicInfluence.com Rankings

Carlos Cordon-Cardo

Biology

#1899

World Rank

#3074

Historical Rank

#890

USA Rank

Pathology

#22

World Rank

#57

Historical Rank

#13

USA Rank

biology Degrees

Carlos Cordon-Cardo

Philosophy

#2760

World Rank

#4625

Historical Rank

#949

USA Rank

Logic

#773

World Rank

#1304

Historical Rank

#274

USA Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Carlos Cordon-Cardo's Degrees

Doctorate Medicine University of Barcelona
PhD Pathology University of Barcelona

Why Is Carlos Cordon-Cardo Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Carlos Cordon-Cardo is a Spanish-born American physician and scientist known for his research in experimental pathology and molecular oncology. He holds the "Irene Heinz Given and John LaPorte Given" Chair in Pathology at Mount Sinai School of Medicine.

(See a Problem?)

Carlos Cordon-Cardo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A microRNA polycistron as a potential human oncogene (2005) (3743)
A multigenic program mediating breast cancer metastasis to bone. (2003) (2521)
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis (2005) (1923)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas (2007) (1896)
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. (1989) (1738)
Role of the INK4a Locus in Tumor Suppression and Cell Mortality (1996) (1675)
The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 (1998) (1637)
Pten is essential for embryonic development and tumour suppression (1998) (1550)
An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (1522)
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis (2003) (1499)
Prostate-specific membrane antigen expression in normal and malignant human tissues. (1997) (1334)
Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice (2001) (1210)
Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach (2006) (1095)
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. (1990) (1040)
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. (1999) (996)
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma (2001) (990)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy (2004) (979)
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months (2020) (939)
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3 (1991) (929)
Essential role for oncogenic Ras in tumour maintenance (1999) (913)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia (2007) (880)
Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis (1996) (780)
Differential exoprotease activities confer tumor-specific serum peptidome patterns. (2005) (730)
Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression (2007) (716)
Pten Dose Dictates Cancer Progression in the Prostate (2003) (707)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (2009) (666)
NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN (2007) (657)
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. (1990) (642)
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. (2007) (627)
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. (2000) (620)
miR-19 is a key oncogenic component of mir-17-92. (2009) (611)
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. (1995) (602)
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis (2004) (598)
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. (1985) (565)
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control (2004) (564)
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. (2006) (556)
Impaired Fas response and autoimmunity in Pten+/- mice. (1999) (552)
p63 expression profiles in human normal and tumor tissues. (2002) (545)
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. (1993) (536)
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. (1994) (528)
Role of PML in cell growth and the retinoic acid pathway. (1998) (525)
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. (1993) (516)
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse (2001) (513)
The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3 (1991) (512)
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants (2005) (463)
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. (2002) (463)
Lipopolysaccharide Induces Disseminated Endothelial Apoptosis Requiring Ceramide Generation (1997) (433)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. (1996) (432)
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. (2008) (429)
Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene (2006) (426)
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. (1997) (425)
AKI in Hospitalized Patients with COVID-19. (2020) (420)
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. (2001) (419)
Identification of a tumour suppressor network opposing nuclear Akt function (2006) (411)
Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification (2003) (411)
SARS-CoV-2 viral load predicts COVID-19 mortality (2020) (396)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas (2011) (380)
Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. (2012) (375)
γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia (2009) (373)
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer (1985) (368)
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo (2003) (368)
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study (2020) (364)
Autocrine PDGFR signaling promotes mammary cancer metastasis. (2006) (349)
Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. (1994) (349)
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. (1992) (345)
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression (2005) (345)
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. (2004) (338)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens (1997) (335)
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR (2006) (327)
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. (1986) (324)
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence (2010) (305)
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. (1999) (303)
HIV antigen in the brains of patients with the AIDS dementia complex (1987) (291)
Loss of p63 expression is associated with tumor progression in bladder cancer. (2002) (288)
Expression of basic fibroblast growth factor in normal human tissues. (1990) (279)
High-resolution characterization of the pancreatic adenocarcinoma genome (2004) (278)
Inactivation of p53 and Pten promotes invasive bladder cancer. (2009) (277)
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. (2003) (277)
Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. (2002) (276)
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas (2007) (276)
Limited overlapping roles of P15INK4b and P18INK4c cell cycle inhibitors in proliferation and tumorigenesis (2000) (274)
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. (1984) (273)
Ku70 Is Required for DNA Repair but Not for T Cell Antigen Receptor Gene Recombination In Vivo (1997) (273)
Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations (2001) (270)
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. (1999) (270)
p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns (1994) (268)
PHF6 mutations in T-cell acute lymphoblastic leukemia (2010) (264)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides (1997) (260)
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 (2020) (259)
Expression of c-kit and kit ligand proteins in normal human tissues. (1994) (257)
Genetic alterations in bladder cancer (1993) (252)
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. (1989) (248)
Molecular genetic alterations in superficial and locally advanced human bladder cancer. (1991) (248)
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. (2006) (248)
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. (1992) (247)
Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. (1998) (242)
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma (2015) (242)
Molecular pathways of urothelial development and bladder tumorigenesis. (2010) (240)
Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations (2007) (236)
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. (1995) (233)
A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia (2014) (230)
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. (1986) (230)
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. (1989) (229)
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. (1997) (229)
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. (2000) (228)
Targeting cancer stem cells to suppress acquired chemotherapy resistance (2014) (228)
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. (2003) (227)
Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism (2005) (226)
MDM2 and prognosis. (2004) (225)
Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. (1998) (218)
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. (2013) (218)
Expression of ras proto-oncogene proteins in normal human tissues. (1987) (218)
Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. (1981) (215)
Altered expression of the retinoblastoma gene product in human sarcomas. (1990) (214)
The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. (2002) (208)
Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. (2003) (207)
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth (1998) (203)
An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer (2000) (200)
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. (2002) (195)
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer (2018) (195)
Deletion of the p16 and p15 genes in human bladder tumors. (1995) (194)
Altered patterns of MDM2 and TP53 expression in human bladder cancer. (1994) (192)
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. (1994) (189)
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. (2007) (188)
Gene discovery in bladder cancer progression using cDNA microarrays. (2003) (187)
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. (2008) (186)
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. (2008) (181)
Inverse associations between plasma lycopene and other carotenoids and prostate cancer. (2001) (180)
Integrative Genome Comparison of Primary and Metastatic Melanomas (2010) (179)
PTEN counteracts FBXL2 to promote IP3R3– and Ca2+–mediated apoptosis limiting tumour growth (2017) (177)
exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids (2019) (177)
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (2018) (177)
Tissue-specific and reversible RNA interference in transgenic mice (2007) (176)
Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. (1999) (176)
Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. (1991) (175)
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. (1989) (175)
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. (2002) (170)
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model, CWR22-R (2000) (169)
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. (2003) (167)
Role of the chromobox protein CBX7 in lymphomagenesis (2007) (167)
Bladder cancers arise from distinct urothelial sub-populations (2014) (167)
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. (2001) (166)
Profiling bladder cancer using targeted antibody arrays. (2006) (165)
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. (1988) (164)
Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study (2020) (163)
p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. (1999) (162)
Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. (1999) (162)
The metabolic co-regulator PGC1α suppresses prostate cancer metastasis (2016) (162)
p27 as a target for cancer therapeutics. (2003) (162)
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells (1987) (161)
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. (1985) (159)
Gene amplification in gastric and esophageal adenocarcinomas. (1990) (159)
Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. (2003) (159)
Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. (1994) (158)
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. (1999) (158)
Desmoid fibromatosis is a clonal process. (1996) (158)
The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. (2000) (157)
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. (2011) (156)
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. (2002) (156)
miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. (2012) (155)
The TLX1 oncogene drives aneuploidy in T-cell transformation (2010) (153)
Amplification of CDK4 and MDM2 in malignant melanoma (2006) (152)
Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression (2001) (149)
Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. (1994) (149)
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence (2010) (147)
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. (1999) (147)
Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. (1993) (146)
At the Crossroads of Inflammation and Tumorigenesis (1999) (146)
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma (2021) (143)
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. (2001) (140)
Mzf1 controls cell proliferation and tumorigenesis. (2001) (139)
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. (1999) (139)
Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma (1994) (139)
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. (1993) (138)
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. (2007) (138)
p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. (1994) (137)
Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience (2021) (136)
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2013) (135)
MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century (2009) (135)
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. (1996) (134)
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months (2020) (130)
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. (2001) (130)
Oncogenes in melanoma (2003) (130)
Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion (2013) (128)
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study (2020) (128)
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. (2008) (125)
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer (2017) (125)
Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? (2009) (125)
Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. (2003) (125)
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. (2009) (124)
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. (2011) (124)
Molecular alterations associated with bladder cancer initiation and progression (2008) (123)
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. (1992) (120)
Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer (2009) (119)
HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. (2001) (118)
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. (2007) (117)
Convalescent plasma treatment of severe COVID-19: A matched control study (2020) (117)
Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in acute lymphoblastic leukemia (2015) (116)
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. (2000) (116)
Improved prediction of prostate cancer recurrence through systems pathology. (2007) (116)
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. (1987) (114)
Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. (1991) (114)
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. (2005) (113)
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. (2006) (113)
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. (1999) (113)
Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. (1999) (112)
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. (2002) (111)
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. (2015) (110)
Identifying site-specific metastasis genes and functions. (2005) (110)
Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. (1985) (110)
Ki‐67 detected by MIB‐1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma (1998) (109)
TREK-1 is a novel molecular target in prostate cancer. (2008) (108)
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. (1989) (107)
Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. (1994) (106)
High-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. (1985) (105)
Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2019) (104)
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. (1998) (104)
Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis (2003) (102)
The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. (2002) (102)
Role of Dok-1 and Dok-2 in Leukemia Suppression (2004) (102)
Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer (1993) (101)
Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. (2000) (101)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. (1998) (100)
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. (2001) (99)
Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. (1995) (99)
Translocation Renal Cell Carcinomas in Adults: A Single-institution Experience (2012) (98)
Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer (2001) (98)
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. (2008) (98)
Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. (2000) (98)
Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. (2000) (97)
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. (1998) (95)
A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol (2005) (95)
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. (1988) (94)
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. (2000) (94)
Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. (1994) (94)
Targeting nonclassical oncogenes for therapy in T-ALL. (2012) (94)
Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. (2002) (94)
Clinical Characteristics of Hospitalized Covid-19 Patients in New York City (2020) (93)
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas (1992) (93)
High Ki‐67 proliferative index predicts disease specific survival in patients with high‐risk soft tissue sarcomas (2001) (93)
Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. (1994) (93)
Racial disparity of epidermal growth factor receptor expression in prostate cancer. (2004) (92)
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms (2021) (92)
Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region (2020) (91)
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer (2004) (91)
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation (2004) (90)
Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. (2002) (90)
Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+ breast cancers (2015) (89)
DNA extraction from paraffin-embedded tissues using a salting-out procedure: a reliable method for PCR amplification of archival material. (1997) (89)
Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia (2015) (89)
Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. (1990) (89)
HDM2 protein overexpression and prognosis in primary malignant melanoma. (2002) (89)
Expression of the retinoblastoma protein is regulated in normal human tissues. (1994) (89)
Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. (1999) (89)
Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. (1988) (88)
Comparison of SARS‐CoV‐2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS‐CoV‐2 test and a laboratory‐developed real‐time RT‐PCR test (2020) (88)
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. (1990) (87)
The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. (1994) (87)
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. (2001) (87)
Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays (2007) (87)
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. (2003) (87)
An inflammatory cytokine signature helps predict COVID-19 severity and death (2020) (86)
Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia (2012) (86)
Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. (1994) (86)
Tumor promotion by Mdm2 splice variants unable to bind p53. (2003) (84)
Molecular profiling of tumor progression in head and neck cancer. (2005) (82)
Molecular Abnormalities of mdm 2 and p 53 Genes in Adult Soft Tissue Sarcomas ' (82)
Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation (2020) (81)
Molecular alterations in bladder cancer. (1998) (81)
Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. (2010) (81)
Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. (1996) (81)
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. (2017) (80)
K-ras mutation in adenomas and carcinomas of the ampulla of vater. (1997) (80)
Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. (2018) (80)
Cyfip1 Is a Putative Invasion Suppressor in Epithelial Cancers (2009) (79)
Reproducibility of p53 Immunohistochemistry in Bladder Tumors (2000) (79)
Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. (2002) (79)
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis (2009) (78)
Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy (2000) (78)
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. (2004) (78)
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. (2014) (77)
FBXW7 mutations in melanoma and a new therapeutic paradigm. (2014) (77)
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. (2002) (77)
Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer (2009) (76)
p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. (2003) (76)
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. (1995) (75)
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma (2020) (74)
Allelic deletions in renal tumors: histopathological correlations. (1993) (74)
Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL (2008) (74)
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. (2008) (73)
Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. (1999) (73)
Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. (2003) (73)
Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic disease (2010) (73)
Neutralizing Antibody Responses in COVID-19 Convalescent Sera (2020) (73)
Biomarkers for bladder cancer management: present and future. (2014) (73)
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation (1988) (73)
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer (2003) (72)
MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9 (2014) (72)
p73α Regulation by Chk1 in Response to DNA Damage (2003) (71)
Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes (2005) (70)
Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. (2004) (70)
Mutation of cell cycle regulators and their impact on superficial bladder cancer. (2000) (70)
A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer (2007) (69)
Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. (1986) (69)
Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. (1987) (68)
Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model (2001) (67)
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. (2002) (67)
Immunohistologic expression of blood‐group antigens in normal human gastrointestinal tract and colonic carcinoma (1986) (67)
A critical role for choline kinase-α in the aggressiveness of bladder carcinomas (2009) (67)
Molecular alterations associated with bladder cancer progression. (2007) (67)
Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. (1987) (66)
Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. (1984) (65)
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. (2016) (64)
Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. (2011) (64)
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. (1994) (64)
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. (1995) (64)
Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. (1998) (63)
Evaluation of the proliferation marker MIB‐1 in the prognosis of cutaneous malignant melanoma (2002) (63)
Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa. (2008) (63)
Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. (1994) (63)
Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy (2019) (63)
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. (2015) (63)
Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. (2008) (62)
Galectin-3 expression is associated with bladder cancer progression and clinical outcome (2010) (62)
The role of GATA2 in lethal prostate cancer aggressiveness (2017) (62)
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. (2012) (62)
Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. (2010) (62)
Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non‐small cell lung cancer (2007) (62)
Expression ofHer2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma (2005) (62)
The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland (2014) (62)
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. (1997) (61)
Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. (1995) (61)
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. (1984) (61)
Gene expression profiling in single cells within tissue (2005) (60)
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. (2000) (60)
Personalized prediction of tumor response and cancer progression on prostate needle biopsy. (2009) (60)
Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. (1989) (60)
Can p53 help select patients with invasive bladder cancer for bladder preservation? (1999) (59)
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. (2005) (59)
Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. (2000) (58)
Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics. (1986) (58)
Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients: A Cohort Study. (2020) (58)
P-glycoprotein expression in brain tumors (1992) (57)
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. (2015) (56)
Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. (1998) (56)
Applications of array technology: identification of molecular targets in bladder cancer (2003) (55)
Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome (2003) (54)
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria. (2015) (54)
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma (2005) (54)
Genetic studies and molecular markers of bladder cancer. (1997) (54)
Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. (2000) (52)
Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. (2011) (52)
Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1 (2007) (52)
Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study. (2007) (51)
MAGE-A3 is highly expressed in a subset of colorectal cancer patients. (2012) (51)
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. (1994) (50)
Inactivation of p 53 and Pten promotes invasive bladder cancer (2009) (49)
Expression of p63 in Diffuse Large B-Cell Lymphoma (2005) (49)
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. (1998) (48)
Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. (2001) (48)
Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue Microarrays (2001) (48)
Critical appraisal of tumor markers in bladder cancer. (1993) (48)
Blood group-related antigens in human kidney: modulation of Lewis determinants in renal cell carcinoma. (1989) (48)
Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies (1985) (47)
p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. (2005) (47)
Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer (2014) (47)
Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. (1996) (47)
Alterations of tumor suppressor genes in bladder cancer. (1997) (47)
Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury (2019) (46)
Immunohistologic dissection of the human kidney using monoclonal antibodies. (1985) (46)
KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. (2011) (46)
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma (2021) (46)
Immunopathology of adrenal and renal cortical tumors. Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex. (1990) (46)
Associations between Variants of the 8q24 Chromosome and Nine Smoking-Related Cancer Sites (2008) (45)
ETS rearrangements and prostate cancer initiation (2009) (45)
Intravenous basic fibroblast growth factor protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. (1995) (45)
Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody (1984) (44)
Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors. (2001) (43)
Single nucleotide polymorphisms of 8 inflammation‐related genes and their associations with smoking‐related cancers (2010) (43)
p73alpha regulation by Chk1 in response to DNA damage. (2003) (43)
Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line (1995) (43)
Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. (1999) (42)
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. (2006) (42)
Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. (1998) (42)
Treatment with high dose mouse monoclonal (anti‐GD3) antibody R24 in patients with metastatic melanoma (1992) (42)
Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. (1997) (42)
A Role for PML in Innate Immunity. (2011) (42)
DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. (1991) (42)
Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. (2010) (41)
COVID-19: Staging of a New Disease (2020) (41)
Identification of PMF1 Methylation in Association with Bladder Cancer Progression (2008) (41)
Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. (2003) (41)
Genetic and Immunophenotype Analyses of TP53 in Bladder Cancer: TP53 Alterations Are Associated with Tumor Progression (2004) (40)
Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer (1996) (39)
Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer. (2004) (39)
Prognostic significance of p27Kip1 expression in bladder cancer (2007) (38)
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies (2020) (38)
Analysis of p21WAF1/CIP1 in primary bladder tumors. (1998) (38)
Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles (2009) (38)
Technology Insight: will systems pathology replace the pathologist? (2007) (38)
The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein (2017) (37)
IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. (1989) (36)
PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer (2015) (36)
Separation of live cells in different phases of the cell cycle for gene expression analysis. (2002) (36)
p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? (2004) (35)
Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors (1998) (35)
p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner (2008) (35)
Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts (2007) (35)
Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin (2004) (35)
Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. (2011) (34)
Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients (2020) (34)
Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. (1988) (34)
The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor β in Mammary Epithelial Cells (2014) (34)
Renal cell carcinoma genetic analysis by comparative genomic hybridization and restriction fragment length polymorphism analysis. (1996) (33)
Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. (1992) (33)
Selective growth of a population of human basophil cells in vitro. (1981) (32)
The multidrug resistance phenotype in human cancer. (1991) (32)
Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. (2007) (32)
TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation (2015) (32)
Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. (2009) (31)
A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2‐T4aN0‐N2M0 bladder cancer (2012) (31)
Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. (2001) (31)
Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hepatocellular carcinoma. (1998) (31)
Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. (2000) (31)
Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors (2007) (30)
Discovery of myopodin methylation in bladder cancer (2008) (30)
Bcl-2 and Bax expression in thyroid tumours An immunohistochemical and Western blot analysis (1997) (29)
Expression Profiling of Osteosarcoma Cells Transfected with MDR1 and NEO Genes: Regulation of Cell Adhesion, Apoptosis, and Tumor Suppression-Related Genes (2003) (29)
Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma (2001) (28)
DNA Microchips: Technical and Practical Considerations (2000) (28)
A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. (2013) (27)
MDM 2 and Prognosis (2004) (27)
Safety and Biologic Activity of Intravenous BCL-2 Antisense Oligonucleotide (G3139) and Taxane Chemotherapy in Patients With Advanced Cancer (2005) (27)
Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury. (2000) (27)
Immunopathologic analysis of a panel of mouse monoclonal antibodies reacting with human ovarian carcinomas and other human tumors. (1985) (26)
Genetic alterations associated with bladder cancer. (1994) (26)
Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas (2003) (26)
Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling. (2013) (26)
Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. (2016) (25)
Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression (2021) (25)
p27 deficiency desensitizes Rb−/− cells to signals that trigger apoptosis during pituitary tumor development (2003) (25)
Blood group-related antigens in human germ cell tumors. (1988) (24)
Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. (1986) (24)
GAB2 induces tumor angiogenesis in NRAS-driven melanoma (2013) (24)
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. (2015) (24)
Chromosome 16 in primary prostate cancer: A microsatellite analysis (1997) (24)
The pathology of low-grade adenosquamous carcinoma of the breast. An immunohistochemical study. (1994) (23)
Differential Expression of DNA Nonhomologous End-Joining Proteins Ku70 and Ku80 in Melanoma Progression (2002) (23)
Enhanced detection of bladder cancer in urine cytology with Lewis X, M344 and 19A211 antigens. (1994) (23)
Apaf-1 expression in malignant melanoma (2006) (23)
CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model. (2012) (23)
Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (2016) (23)
Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City (2020) (23)
Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. (1989) (23)
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis (2006) (23)
Cigarette smoking and chromosome 9 alterations in bladder cancer. (1997) (22)
Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines (1996) (22)
Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer (2021) (22)
Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts. (1993) (22)
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. (2004) (22)
Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer. (1997) (22)
Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. (2001) (22)
Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice. (1995) (21)
Differentiation antigens of melanoma and melanocytes. (1986) (21)
Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test (2018) (21)
Comparison of models to predict clinical failure after radical prostatectomy (2009) (21)
RT‐PCR/MALDI‐TOF mass spectrometry‐based detection of SARS‐CoV‐2 in saliva specimens (2021) (21)
A context dependent role for Wnt signaling in tumorigenesis and stem cells (2008) (20)
Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies. (2004) (20)
Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours (2004) (20)
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. (1997) (20)
Predicting high-risk disease using tissue biomarkers (2013) (20)
Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase binding protein. (1987) (20)
GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis. (2002) (19)
The Ink4a Tumor Suppressor Gene Product, p19 Arf , Interacts with MDM2 and Neutralizes (1998) (19)
Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer. (1995) (19)
Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity. (2006) (19)
Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR (2018) (19)
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients (2022) (19)
Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma (2015) (19)
ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. (2015) (19)
Alterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma. (2001) (18)
Expression of blood group antigens in bladder cancer: current concepts. (1992) (18)
Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis. (2003) (18)
Expression of P-glycoprotein in normal muscle cells and myogenic tumors. (1992) (18)
P53 restoration in liver carcinomas induces cellular senescence and tumor clearance through an innate immune response (2006) (18)
Immunohistochemical localization of la nuclear antigen in brain Selective concentration of the la protein in neuronal nucleoli (1985) (18)
Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN (2015) (18)
Reappraising hyalinizing clear cell carcinoma: A population‐based study with molecular confirmation (2017) (18)
Systems pathology (2009) (17)
PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation (2012) (17)
Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis (2011) (17)
Alterations in the retinoblastoma pathway of cell cycle control in parathyroid tumors. (2000) (17)
Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder. (1985) (17)
Blood group antigens in normal and neoplastic urothelium (1992) (17)
Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth. (2011) (16)
Analysis of sex-specific risk factors and clinical outcomes in COVID-19 (2021) (16)
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. (2004) (16)
Methodological issues in the use of tumour markers in cancer epidemiology. (1997) (16)
Mouse monoclonal IgG 3 antibody detecting GD 3 ganglioside : A phase I trial in patients with malignant melanoma ( complement activation / inflammation / immunotherapy ) (2003) (16)
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. (2015) (16)
Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target (2015) (16)
Limited miR-17-92 overexpression drives hematologic malignancies. (2015) (16)
OPSOCLONUS AND OAT CELL CARCINOMA OF LUNG: LACK OF EVIDENCE FOR ANTI-CNS ANTIBODIES (1984) (16)
Cell‐surface antigens of human lung tumors detected by mouse monoclonal antibodies: Definition of blood‐group‐ and non‐blood‐group‐related antigenic systems (1990) (16)
Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. (2006) (15)
Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib (2004) (15)
A monoclonal antibody that induces T cell aggregation reacts with vascular endothelial cells and placental trophoblasts. (1986) (15)
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. (2009) (15)
Initial evaluation of a new epithelial antigen (T16) for bivariate flow cytometry of bladder irrigation specimens. (1989) (15)
Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019 (2021) (14)
A Novel Logistic Model Based on Clinicopathological Features Predicts Microsatellite Instability in Colorectal Carcinomas (2005) (14)
Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. (2002) (14)
Expression of the retinoblastoma gene product in renal tumors. (1996) (14)
Immunohistochemical characterization of two monoclonal antibodies, P25.48 and P25.91, which define a new prostate-specific antigen. (1988) (14)
MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. (2021) (14)
A BAC-Based Transgenic Mouse Specifically Expresses an Inducible Cre in the Urothelium (2012) (13)
Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. (2014) (13)
Neural network predicts sequence of TP53 gene based on DNA chip (2002) (13)
Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis (2018) (13)
Applications of Molecular Diagnostics: Solid Tumor Genetics Can Determine Clinical Treatment Protocols (2001) (13)
Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. (2018) (13)
Immunohistochemical Analysis of P-Glycoprotein Expression in Normal and Tumor Tissues in Humans (1991) (13)
Broad SARS-CoV-2 cell tropism and immunopathology in lung tissues from fatal COVID-19 (2020) (13)
Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases. (2004) (12)
Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. (2006) (12)
The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL. (2009) (12)
Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. (2017) (12)
Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. (2002) (11)
Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors (1995) (11)
Drg 1 Expression in 131 Colorectal LiverMetastases : Correlation with ClinicalVariables and Patient Outcomes (2005) (11)
Mouse monoclonal antibody detecting G(D3) ganglioside: A phase I trial in patients with malignant melanoma (1985) (11)
H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. (2016) (11)
Prognostic role of cyclin D1 in retroperitoneal sarcomas (2001) (11)
Mouse Models of Human Bladder Cancer as a Tool for Drug Discovery (2010) (11)
Expression Profiles in Human Normal and Tumor Tissues 1 (2002) (11)
Targeting sarcoma tumor-initiating cells through differentiation therapy. (2017) (10)
Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave (2021) (10)
Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis. (2004) (10)
Association of type 1 blood group antigens with urinary tract infections in children with genitourinary structural abnormalities. (1990) (10)
A new polymorphic site in intron 2 of TP53 characterizes LOH in human tumors by PCR-SSCP. (1995) (9)
Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes (2017) (9)
On the origins of clinical drug resistance. (1991) (9)
Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. (2006) (9)
Altered Expression of p 27 and Skp 2 Proteins in Prostate Cancer of African-American Patients 1 (2003) (8)
Application of in situ hybridization probes for MLH-1 and MSH-2 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemistry and tumor stage. (2004) (8)
Loss of Ku70/Ku80 expression occurs more frequently in hereditary than in sporadic colorectal tumors. Tissue microarray study. (2006) (8)
Cell Cycle Regulators as Prognostic Factors for Bladder Cancer (1998) (8)
BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer (2001) (8)
Expression in Human Normal and Tumor Tissues : Loss of p 73 Expression Is Associated with Tumor Progression in Bladder Cancer (2003) (8)
Blood group antigen expression in bladder tumors: An immunohistochemical study of superficial bladder lesions (1994) (8)
Tumor Promotion by Mdm 2 Splice Variants Unable to Bind p 531 (2003) (8)
MAGE-A 3 is highly expressed in a subset of colorectal cancer patients (2011) (8)
DNA extraction from paraff in-em bedded tissues using a salting-out procedure : a reliab method for PCR amplification of archiva 1 mate (2010) (8)
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer (1998) (8)
Antemortem detection of Parkinson’s disease pathology in peripheral biopsies using artificial intelligence (2022) (8)
Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10‐year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery (2012) (8)
Molecular Profiling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms (2021) (8)
A systems‐based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long‐term outcome in men with localized prostate cancer (2012) (8)
Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. (1994) (7)
Relationship of nm23 expression to proliferation and prognosis in malignant melanomas of the oral cavity. (2005) (7)
Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases. (2005) (7)
A Case‐Series Study of p53 Nuclear Overexpression in Early‐Stage Stomach Cancer (1995) (7)
Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. (2004) (7)
[Pure sensory neuropathy. Restriction of the Hu antibody to the sensory neuropathy associated with small cell carcinoma of the lung]. (1986) (7)
Cell surface differentiation antigens of normal urothelium and bladder tumors. (1992) (7)
Bladder cancer: advances in biology and treatment. (1994) (7)
Robust clinical detection of SARS‐CoV‐2 variants by RT‐PCR/MALDI‐TOF multitarget approach (2021) (7)
Immunopathologic Assessment of PTEN Expression. (2016) (7)
Mutation of Cell Cycle Regulators (2007) (7)
Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma. (1994) (6)
A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer. (2005) (6)
Critical role of Dok-1 and Dok-2 in leukemia suppression (2004) (6)
Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers (2014) (6)
Evaluation and validation of an RT‐PCR assay for specific detection of monkeypox virus (MPXV) (2022) (6)
Risk factors and p53 nuclear overexpression in early stage intestinal-type adenocarcinoma of the stomach. (1995) (6)
Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies (2021) (6)
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel (2017) (6)
Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs). (2016) (6)
Protein Profiling of Bladder Urothelial Cell Carcinoma (2016) (6)
GADD 153 is an independent prognostic factor in melanoma : immunohistochemical and molecular genetic analysis (2002) (5)
Isolation of cancer stem cells from human prostate cancer samples. (2014) (5)
The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic (2021) (5)
Association of SARS-CoV-2 viral load at admission with in-hospital acute kidney injury: A retrospective cohort study (2021) (5)
At the crossroad of tumorigenesis: drivers and hitchhikers. (1999) (5)
exRNA Signatures in Extracellular Vesicles and their Tumor-Lineage from Prostate Cancer (2020) (5)
Evaluation of Ki 67 , p 53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy : A Southwest Oncology Group study (2006) (5)
Molecular tracing of prostate cancer lethality (2020) (5)
Improved prediction of PSA recurrence through systems pathology. (2004) (5)
Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients (2021) (4)
Hotspots for SARS‐CoV‐2 Omicron variant spread: Lessons from New York City (2022) (4)
Advances in Brief p 14 ARF Silencing by Promoter Hypermethylation Mediates Abnormal Intracellular Localization of MDM 21 (2001) (4)
Reproducibility of p 53 Immunohistochemistry in Bladder Tumors 1 (2000) (4)
Prognostic relevance of histologic grading, the cell cycle-associated antigen Ki-S1 and cell cycle regulators in malignant fibrous histiocytomas: a multivariate analysis. (1998) (4)
Relevance of ploidy related parameters for prognosis in malignant fibrous histiocytomas. (1999) (4)
Artificial intelligence-derived neurofibrillary tangle burden is associated with antemortem cognitive impairment (2022) (4)
Extracellular vesicles carry distinct proteo-transcriptomic signatures that are different from their cancer cell of origin (2021) (4)
Involvement of the Ink4a gene (p16 and p19arf) in murine tumorigenesis. (1999) (4)
Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis (2017) (4)
Allotype imbalance or microsatellite mutation in low‐grade soft tissue sarcomas of the extremities in adults (2002) (4)
Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer. (2009) (4)
Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. (2021) (4)
Proposal of a new grading system for malignant fibrous histiocytomas. (2005) (4)
Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. (2012) (4)
Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL (2008) (3)
Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL. (2007) (3)
Monoclonal Antibodies in the Diagnosis of Solid Tumors: Studies on Renal Carcinomas, Transitional Cell Carcinomas, and Melanoma (1985) (3)
Cancer Xenograft Model CWR 22-R Nonresponsive Genes in the Androgen-independent Prostate Dysregulated Expression of Androgen-responsive and Updated Version (2000) (3)
Quantitative Analysis of Ku70 and Ku80 mRNA Gene Expression in Melanoma Brain Metastases. Correlation with Immunohistochemistry and In Situ Hybridization. (2004) (3)
[The AIDS virus]. (1986) (3)
p73 hhh -Mediated Apoptosis Requires p57 kip2 Induction and IEX-1 Inhibition (2005) (3)
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic (2021) (3)
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization (2022) (3)
Food for thought: Eating before saliva collection and interference with SARS‐CoV‐2 detection (2022) (3)
Perioperative Polyphenon E, a Green Tea Extract, Does Not Affect the Wound Complication Rate in Mice After Sham Laparotomy yet Has an Inhibitory Effect on Wound Healing (2012) (3)
HDM 2 Protein Overexpression , but not Gene Amplification , is Related to Tumorigenesis of Cutaneous Melanoma 1 (2001) (2)
5. Renal and Transitional Carcinomas (1987) (2)
Immunopathology--new help for the clinician. (1988) (2)
Unannotated small RNA clusters in circulating extracellular vesicles detect early stage liver cancer (2020) (2)
O100 DISCOVERY OF NOVEL MUTATIONS AND FUSION PROTEINS IN INTRAHEPATIC CHOLANGIOCARCINOMA (2014) (2)
Preclinical Development Preclinical Analysis of the g-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia (2012) (2)
Correlate with Levels of Thymidylate Synthase Colon Cancer As Compared with Hepatic Metastasis and Levels of E 2 F-1 Expression Are Higher in Lung Metastasis of Updated (2000) (2)
A putative tumor suppressor role for Wnt-signaling in sarcomagenesis. (2006) (2)
Cancer-specific associations of driver genes with immunotherapy outcome (2020) (2)
Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas (1992) (2)
Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multi-target approach (2021) (2)
The human leukocyte antigen as a candidate tumor suppressor. (2021) (2)
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells (2020) (2)
486 DISCOVERY OF DNA HYPERMETHYLATION OF BDNF, SOX9 AND PMF1 ASSOCIATED WITH BLADDER CANCER PROGRESSION USING CPG ISLAND ARRAYS (2007) (2)
Evaluation of alterations in the tumor suppressor genes INK4A and INK4B in human bladder tumors. (2002) (2)
Monoclonal Antibodies to Renal Cancer Markers (1985) (2)
Gene Amplification in Gastric and Esophageal Adenocarcinomas1 (2006) (2)
Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer (2018) (2)
Corrigendum: Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer (2011) (2)
Relation between Human Papillomavirus Positivity and p 16 Expression in Head and Neck Carcinomas – A Tissue Microarray Study (2008) (2)
Featured Review Article Biomarkers for bladder cancer management: present and future (2014) (2)
Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas. (2006) (2)
Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report (2021) (2)
Molecular Profiling of COVID-19 Autopsies Uncovers Novel Disease Mechanisms (2021) (1)
1321: Delineating Genetic Signatures of Lymph Node Metastases in Bladder Cancer Using Oligonucleotide Microarrays (2005) (1)
COMMENT ON : DISTINCT ALTERED PATTERNS OF P27KIP1 GENE EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC CARCINOMA. AUTHOR'S REPLY (1999) (1)
Recent diagnostic modalities for bladder cancer. (1990) (1)
Comparison of DNA ploidy status and DNA ploidy-related parameters in malignant melanoma tissue microarrays and full sections. (2004) (1)
An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL (2012) (1)
385 DELTAN P63 (ΔNP63) EXPRESSION AS A PROGNOSTIC FACTOR OF PROGRESSION IN CLINICAL HGT1 BLADDER CANCER (2012) (1)
Relationship between DNA mismatch repair genes expression, Ku-genes expression and ploidy-related parameters in the progression of pigmented lesions of the skin. (2002) (1)
Related to Tumorigenesis of Cutaneous Melanoma HDM 2 Protein Overexpression , but not Gene Amplification , is Updated (2001) (1)
Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival (2012) (1)
Prostate cancer prognosis via integrative and co-localized glandular morphometry and immunofluorescent protein biomarker expression. (2015) (1)
Whole Slide Imaging for Teleconsultation: The Mount Sinai Hospital, Labcorp Dianon, and Philips Collaborative Experience (2021) (1)
Class ificat ion of Clear-Cel l Sarcoma as a Subtype of Melanoma by Genomic Profil ing (2003) (1)
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2020) (1)
Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer (2023) (1)
Tumor-specific serum peptidome patterns. (2006) (1)
RT-PCR/MALDI-TOF Diagnostic Target Performance Reflects Circulating SARS-CoV-2 Variant Diversity in New York City (2021) (1)
Mutations of the PML tumor suppressor gene in APL (2003) (1)
Loss of avidin-binding activity in renal cell carcinoma (1990) (1)
Immune response of cancer patients: Analysis with human monoclonal antibodies (1984) (1)
Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer (2022) (1)
Clinical Trial of Radiolabelled Monoclonal Antibody (mAb) Imaging in Patients with Metastatic Renal Cancer (1987) (1)
Molecular and Systems Pathology in Prostate Cancer (2012) (1)
In vivo Bioluminescence Imaging of Luciferase-labeled Cancer Cells (2016) (1)
Comparison of SARS-CoV-2 detection in Saliva by real-time RT-PCR and RT-PCR/MALDI-TOF Methods (2021) (1)
Biochemical and immunologic diagnosis of cancer. Melanoma. (1987) (1)
818: Protein Expression Profiles for JAG-1 and NFK-B Suggest Converging Roles in Prostate Cancer Progression (2006) (1)
Systems pathology for building predictive models: The androgen receptor as a prototype biomarker in prostate cancer progression and targeted therapeutic response assessment. (2006) (1)
Analysis of the p53-hMDM2-p21 (WAF1/CIP1) Cell Cycle Regulation Pathway in Malignant Fibrous Histiocytomas. (2004) (1)
Reversal of glucocorticoid resistance by the g-secretase inhibitor PF-03084014 in T-cell acute lymphoblastic leukemia. (2011) (1)
Personalized approach to prostate cancer prognosis. (2010) (1)
Methylation of the MLH1 and APC promoter regions correlate with decreased and lost expression of MLH1 and APC in melanoma brain metastases (2004) (1)
The Cancer Testis Antigens CABYR a/b and CABY C Are Expressed in a Subset of Colorectal Cancers and Hold Promise as Targets for Specific Immunotherapy (2011) (1)
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment (2021) (1)
T1635 Expression of the Cancer Testis Antigen IGF2BP3 (IMP3) in Colorectal Cancers; IMP3 Holds Promise as a Specific Immunotherapy Target (2010) (1)
NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine (2021) (1)
Food for thought: Eating before saliva collection and interference with SARS-CoV-2 detection (2021) (1)
Abstract 965: An oncogenic metabolic switch mediates resistance to NOTCH1 inhibition in T-ALL (2014) (1)
Cancer stem cells. (2010) (1)
Abstract 2405: Identification of PHLPP as a tumour suppressor reveals the role of pathway feedback compensation in PTEN-mutant prostate cancer progression (2011) (1)
A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants (2022) (1)
Consensus Report, 1987 (1987) (1)
Androgen receptor (AR) level in the prostatectomy specimen predicts time to disease progression post androgen suppression therapy (2007) (1)
Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers (2014) (1)
Diagnostic sub-classification of non-small cell lung cancer: Importance in clinical therapeutics and prognostication (2005) (1)
Personalized approach to prostate cancer prognosis. (2011) (1)
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts (2019) (1)
Pan-Stage Real Time PCR for quantitation of Trypanosoma cruzi parasitic loads in blood samples. (2022) (1)
A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants (2022) (1)
Serological Dissection of Human Breast Cancer with Mouse and Human Monoclonal Antibodies (1985) (1)
P-glycoprotein expression in retinoblastoma (2005) (1)
Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes (2016) (1)
DISCOVERY OF THE METHYLATION OF THE METASTASIS SUPPRESSOR GENE, KISS-1, IN BLADDER CANCER (2009) (1)
772: Identification of Genetic Signatures Associated with TP53 Status in Patients with Bladder Cancer (2005) (1)
Biochemical and immunologic diagnosis of cancer. Functional histopathology. (1987) (1)
Development and characterization of a new monoclonal antibody against SARS‐CoV‐2 NSP12 (RdRp) (2022) (1)
30th Annual Meeting • American Society of Preventive Oncology, Bethesda, Maryland • February 26–28, 2006 (2006) (0)
β-catenin loss-of-function and its putative role as a tumor suppressor in sarcomagenesis (2006) (0)
Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation (Preprint) (2020) (0)
The effect of mitotic checkpoint defects on chromosome stability in mammals (2005) (0)
Antemortem detection of Parkinson’s disease pathology in peripheral biopsies using artificial intelligence (2022) (0)
Advances in Brief 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2 / neu and Inhibits the Growth of Prostate Cancer Xenografts 1 (2002) (0)
ΔNp63 is critical for progression of high grade non-muscle invasive bladder cancer through deregulation of specific genetic pathways (2016) (0)
Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years (2022) (0)
Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test (2018) (0)
HISTOLOGICAL VALIDATION OF MYOCARDIAL AMYLOID QUANTIFICATION WITH CARDIAC MAGNETIC RESONANCE T1 MAPPING (2014) (0)
1774: Predicting Disease Specific Survival at the Time of Diagnosis Utilizing Clinical Variables Integrated with Quantitative Immunofluorescence (2007) (0)
Back Cover Image, Volume 94, Number 6, June 2022 (2022) (0)
Expression of Lewis3, Lewis", X, and Y Blood Group Antigens in Human Colonie Tumors and Normal Tissue and in Human Tumor-derived Cell Lines1 (2006) (0)
Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2019) (0)
RNA interference against cancer associated genes (2006) (0)
Specificity analysis of mouse mono4 surface antigens of human renal ca (differentiation antigens/immunopathology/adenosine deaminase bin (2016) (0)
Adenocarcinomas Gene Amplification in Gastric and Esophageal Updated Version (1990) (0)
[Multiple drug resistance. Biological and clinica implications]. (1989) (0)
Cancer esearch or and Stem Cell Biology act of Stromal Sensitivity on Radiation Response R umors Implanted in SCID Hosts Revisited (2010) (0)
Expression profiling of osteosarcoma-transfected cells with MDR1 and NEO (2001) (0)
SHORT COMMUNICATION Molecular Pro ﬁ ling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms (2021) (0)
Development and Validation of a Digital-Artificial Intelligent (AI) enabled Assay to predict early-stage breast cancer recurrence (2022) (0)
From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine (2010) (0)
Employing multiplex immunofluorescence to quantify Her2 and phosphorylated Her2 in formalin-fixed, paraffin-embedded breast tumor specimens (2009) (0)
Author Correction: Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2020) (0)
[DNA analysis in stomach cancer--correlation of aneuploidy with tumor site]. (1993) (0)
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer (2011) (0)
Incorporation of advanced image analysis in novel post-prostatectomy systems pathology models as an approach to replace the clinical Gleason and provide robust risk stratification. (2015) (0)
[The barley cell or mastocyte: cellular and molecular biology]. (1985) (0)
THE EFFECT OF ERYTHROPOIETIN ON ISCHEMIC DAMAGE IN THE CANINE KIDNEY (2008) (0)
Adrenocortical C arcinoma: C linical, M orphologic, a nd Molecular C haracterization (2011) (0)
[Antigens and antigenic systems]. (1987) (0)
[Morphologic changes and pathologic anatomy associated with acquired immune deficiency syndrome]. (1986) (0)
Biochemical and immunologic diagnosis of cancer. Neuroblastoma. (1987) (0)
Molecular Profiling of Bladder Cancer Using High-Throughput DNA Microarrays (2003) (0)
Analysis of the expression of selected cell cycle regulators and DNA-repair genes in oral cancer (2004) (0)
Ronald A. DeLellis, M.D., recipient of the 1999 Fred W. Stewart Award. (2000) (0)
Cellular and molecular heterogeneities and signatures, and pathological trajectories of fatal COVID-19 lungs defined by spatial single-cell transcriptome analysis (2023) (0)
[Antigenic determinants in blood groups: past, present and future]. (1989) (0)
Characterization of a human monoclonal antibody (hmAb) (EV248) reactive with an apparently tumor-restricted differentiation antigen (1985) (0)
Family history ofcancer,bodyweight, andp53nuclear overexpression in Duke's Ccolorectal cancer (1995) (0)
Author Correction: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (2020) (0)
Abstract 1096: Hiding from chemo: Leukemic cells forming tumors to survive. (2013) (0)
[Updating of prognostic factors in bladder carcinoma]. (1991) (0)
Biochemical and immunologic diagnosis of cancer. Renal and transitional carcinomas. (1987) (0)
Abstract A08: Race and aggressive prostate cancer: Resolving bias introduced by treatment selection. (2012) (0)
Abstract 2598: The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, augments DNA damage repair and predicts therapy responses (2023) (0)
epithelium in the involuting mammary gland cluster orchestrates remodeling of the miR-424 ( 322 ) / 503 The Material Supplemental (2014) (0)
Clinical significance of the AKT pathway in small cell lung cancer and other neuroendocrine tumors: P1-181 (2007) (0)
Genomic Analysis of Epithelial Ovarian Cancer (2019) (0)
Treatment of Malignant Melanoma with a Mouse Monoclonal IgG3 Antibody Detecting the Ganglioside GD3 (1986) (0)
601: Molecular Profiling of Bladder Cancer Xenografts Treated with COX-2 Inhibitors (2005) (0)
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (2018) (0)
727: Prognostic Significance of the PTEN/AKT Pathway in Bladder Cancer (2004) (0)
1457 XENOTROPIC MURINE LEUKEMIA VIRUS RELATED VIRUS (XMRV) IS PRESENT IN MALIGNANT PROSTATE TISSUE BUT DOES NOT AFFECT PATHOLOGICAL OR CLINICAL OUTCOME (2011) (0)
Modeling leiomyosarcoma in the mouse (2006) (0)
Correlations Allelic Deletions in Renal Tumors : Histopathological Updated (2007) (0)
OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment (2021) (0)
Characteristics Associated With Disparities Among Older Adults in Coronavirus Disease 2019 Outcomes in an Academic Health Care System (2022) (0)
Researching COVID to enhance recovery (RECOVER) autopsy study protocol: Rationale, objectives, and design (2023) (0)
Classification o f C lear-Cell S arcoma a s a S ubtype o f M elanoma by G enomic P rofiling (2003) (0)
Detection of γH2AX foci as a marker for repair of radiation-induced DNA damage in vitro and in vivo (2005) (0)
Abstract 733: A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer (2015) (0)
The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses. (2023) (0)
Relation between RNA expression of DNA repair genes and ifosfamide chemotherapy of melanomas in vitro (2004) (0)
[Applications to clinico-pathological diagnosis of in situ hybridization]. (1990) (0)
409: A Systems Pathology Approach to Predict Survival after Radical Prostatectomy (2005) (0)
Abstract 4091: RapidCap: A new generation of mouse models for prostate cancer. (2013) (0)
Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. (2019) (0)
Retraction for Gonzalez et al., “p73α Regulation by Chk1 in Response to DNA Damage” (2017) (0)
The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses (2023) (0)
Representational oligonucleotide microarray (ROMA) identifies cIAP1/cIAP2 as candidate oncogenes in mouse and human hepatocarcinogenesis-validation of cIAP1 as a therapeutic target in liver cancer in a new mouse model of hepatocellular carcinoma (2005) (0)
Myogenic Regulatory Protein Expression inAdult Soft Tissue Sarcomas (1994) (0)
RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Re ﬂ ects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City (0)
The Role of Microarray Technologies in Bladder Cancer Management (2009) (0)
MP09-12 AN AUTOMATED NOVEL DEEP LEARNING H&E IMAGE ANALYSIS PLATFORM OUTPERFORMS CLINICAL ONLY MODELS AND GLEASON GRADING TO PREDICT POSTOPERATIVE DISEASE RECURRENCE (2020) (0)
Advances in Brief Response of Prostate Cancer to Anti-Her-2 / neu Antibody in Androgen-dependent and-independent Human Xenograft Models 1 (1999) (0)
Abstract 1730:DACH1gene deletion extends portraits of human prostate cancer (2019) (0)
M1847 The Effect of Toll Like Receptor (TLR) 9 Agonist, CpG Oligodeoxynucleotides (ODN), On Abdominal and Gastrotomy Wound Healing in a Murine Model (2008) (0)
Pokemon represses art in promoting cellular transformation (2005) (0)
Abstracts reprinted from journal of clinical oncology (2007) (0)
ADENOSINE DEAMINASE EXPRESSION BY MELANOCYTES (2003) (0)
783: Suppression of Bladder Cancer Growth by a Replication-Competent Retroviral Transfer of Escherichia Coli Purine Nucleoside Phosphorylase and Fludarabine Phosphate in Nude Mice (2005) (0)
Abstract P3-05-21: A novel AI-digital Test with an automated approach for grading and phenotyping breast cancer enriches recurrence score risk prediction in an Oncotype evaluated cohort (2023) (0)
265: A Constitutively Activated Mutant form of Propsa that Manifests Catalytic Action Increases Cell Invasion in Vitro and Frequency of Pulmonary Metastases in vivo in a Subcutaneous Mouse Xenograft Model (2007) (0)
N-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL (2014) (0)
PREDICTION OF DISEASE PROGRESSION INCLUDING DURABLE RESPONSE TO HORMONAL THERAPY AT DIAGNOSIS, USING THE PROSTATE NEEDLE BIOPSY AND PRETREATMENT CLINICAL VARIABLES (2009) (0)
The 1996 Fred W. Stewart Award. Lance A. Liotta, M.D., Ph.D., Recipient of the 1996 Fred W. Stewart Award. (1997) (0)
Characterization of lymphoid infiltrates in prostatectomy specimens post neoadjuvant hormonal therapy using quantitative immunofluorescence and RNA FISH. (2009) (0)
IClinical Trial of the Sequential Combination of Irinotecan Followedby Flavopiridol (2005) (0)
[Immunopathology (II)]. (1985) (0)
Creating surveillance data infrastructure using laboratory analytics: Leveraging visiun and epic systems to support COVID-19 pandemic response (2022) (0)
Reuven Agami Tumorigenicity of the miR-1792 cluster distilled Service Email (2009) (0)
Abstract 436: ΔNp63 is critical for progression of high grade non-muscle invasive bladder cancer to muscle-invasive disease (2014) (0)
Assay to screen compounds that selectively reduce the number of cancer stem cells (2012) (0)
756 - Transcriptional regulation of prostate cancer metabolism (2016) (0)
High-Molecular-Weight Glycoproteins of Human Teratocarcinoma Defined by Monoclonal Antibodies to Carbohydrate Determinants 1 (2006) (0)
Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination (2022) (0)
1706 CARBOPLATIN VS. CISPLATIN-BASED CHEMOTHERAPY IN THE PERIOPERATIVE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER (2010) (0)
Characterization of molecular features of pediatric urothelial bladder carcinomas. (2015) (0)
Author Correction: Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2020) (0)
Renal Cell Carcinomas Specific Region of the Human Proximal Tubule and Subsets Analysis of a Mouse Monoclonal Antibody That Reacts with a Updated (2006) (0)
leukemia Mutations of the PML tumor suppressor gene in acute promyelocytic (2013) (0)
Current Prospects for the Use of Molecular Markers in Treatment of Bladder Cancer by Cystectomy or Bladder-Conserving Approaches (2001) (0)
OUTCOME PREDICTION IN BLADDER CANCER USING OLIGONUCLEOTIDE MICROARRAYS (2008) (0)
Resistance in Patients ' Tumors : Consensus Recommendations Methods to Detect P-Glycoprotein-associated Multidrug Updated (2006) (0)
Positron Emission Tomography of a Human Prostate Cancer Xenograft : Association of Changes in Deoxyglucose Accumulation with Other Measures of Outcome following Androgen Withdrawal 1 (2006) (0)
Screening peripheral biopsies for alpha‐synuclein pathology using deep machine learning (2020) (0)
Ovarian Cancer – Challenges & Innovations (2019) (0)
136 POSTER Discovery of DNAa hypermethylation targets associated with baldder cancer progression using CpG island microarrays (2006) (0)
A systems pathology approach to predict prostate cancer progression, post radical prostatectomy, at the time of diagnosis: Interim results from a multi-center study (2008) (0)
Function of microRNA activity by ActMiR in bladder cancer. (2016) (0)
circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment (2022) (0)
Abstract 2258: Myc drives Pten/ p53-deficient proliferation and metastasis due to Il6-secretion and Akt-suppression via Phlpp2 (2015) (0)
SARS‐CoV‐2 infection of kidney tissues from severe COVID‐19 patients (2023) (0)
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2020) (0)
Applications of artificial intelligence in prostate cancer histopathology. (2023) (0)
C16-Ceramide Elevations in COVID-19-Associated ARDS (2022) (0)
An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (0)
Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC). (2016) (0)
COMBINATORIAL P53 AND PTEN INACTIVATION PROMOTES INVASIVE BLADDER CANCER (2009) (0)
1705 SYSTEMIC CHEMOTHERAPY REGIMEN INFLUENCES OUTCOME IN ADVANCED BLADDER CANCER (2010) (0)
Monoclonal antibodies against human kidney cancer antigens and procedures. (1984) (0)
Myc drives Pten / p 53-deficient proliferation and metastasis due to Il 6-secretion and Akt-suppression via Phlpp 2 RUNNING TITLE : Il 6 drives Myc in Pten-mutant prostate metastasis (2015) (0)
982: A Multianalyte Biosensor for Bladder Cancer Diagnostics (2006) (0)
367 NOVEL P53-INDEPENDENT FUNCTIONS OF ARF IN THE CONTEXT OF COMBINED FUNCTINAL LOSS OF P53 AND PTEN IN A MOUSE MODEL OF INVASIVE BLADDER CANCER (2011) (0)
The role of FGFR4 polymorphism in the development and progression of bladder cancer (2005) (0)
1701 SYSTEMIC CHEMOTHERAPY REGIMEN FOR BLADDER CANCER INFLUENCES OUTCOME IN NEOADJUVANT AND ADJUVANT SETTINGS (2010) (0)
Cyclin E in Bladder Cancer Cycle: Disruption of the Nucleoplasm-Nucleolar Shuttling of Intranuclear Compartmentalization of Cyclin E during the Cell (2001) (0)
7 INVITED Developing combination therapies for hormone-refractory prostate cancer in a pre-clinical mouse model of the disease (2008) (0)
Abstract 2226: Precise stratification of immunotherapy outcomes using response-associated somatic mutations (2020) (0)
Dysregulation of PTEN-AKT axis promotes progression of malignant melanomas (2004) (0)
W1756 Expression of the Cancer Testis Antigens PLAC1 and MAGE3A in Colon Tumors As Potential Targets for Specific Immunotheraphy for a Subset of CRC Patients (2009) (0)
A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program. (2014) (0)
1361 GENE EXPRESSION PROFILES IN PATIENTS WITH UROTHELIAL CANCER UNDERGOING RADICAL CYSTECTOMY (2011) (0)
Carcinomas Derived from Bipotential Liver Progenitors Generation and Analysis of Genetically Defined Liver (2006) (0)
2053 SYSTEMS-BASED PROSTATE CANCER PRE-TREATMENT MODELS RE-CLASSIFY SOME HIGH RISK PATIENTS AS LOW RISK FOR DISEASE PROGRESSION AND INCORPORATE H&E MORPHOMETRY WHICH RELIABLY DISCRIMINATES LOW AND HIGH GLEASON GRADES IN THE PROSTATE NEEDLE BIOPSY (2010) (0)
253: Serum-Based Classification of Patients with Bladder Cancer Using Antibody Arrays (2004) (0)
PTEN levels are controlled by a nuclear transport receptor in lung cancer (2013) (0)
Phylogenetic landscape of Monkeypox Virus (MPV) during the early outbreak in New York City, 2022. (2023) (0)
Contents (2020) (0)
Thymidylate S ynthase E xpression i n H epatic T umors I s a Predictor o f S urvival a nd P rogression i n P atients W ith Resectable M etastatic C olorectal C ancer (2003) (0)
Expression of Class I and Class II Major Histocompatibility Complex (MHC) Antigens in Renal Cell Carcinoma (RCC) (1987) (0)
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer (2018) (0)
BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia (2010) (0)

This paper list is powered by the following services:

Other Resources About Carlos Cordon-Cardo

en.wikipedia.org

What Schools Are Affiliated With Carlos Cordon-Cardo?

Carlos Cordon-Cardo is affiliated with the following schools:

Carlos Cordon-Cardo's Academic­Influence.com Rankings

Carlos Cordon-Cardo's Degrees

Why Is Carlos Cordon-Cardo Influential?

Carlos Cordon-Cardo's Published Works

Published Works

Other Resources About Carlos Cordon-Cardo

What Schools Are Affiliated With Carlos Cordon-Cardo?

Carlos Cordon-Cardo's AcademicInfluence.com Rankings